Review





Similar Products

tim3 galectin 9 pathway  (Galectin Therapeutics)
86
Galectin Therapeutics tim3 galectin 9 pathway
Tim3 Galectin 9 Pathway, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tim3 galectin 9 pathway/product/Galectin Therapeutics
Average 86 stars, based on 1 article reviews
tim3 galectin 9 pathway - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
pe anti tim3  (Cytek Biosciences)
92
Cytek Biosciences pe anti tim3
Pe Anti Tim3, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe anti tim3/product/Cytek Biosciences
Average 92 stars, based on 1 article reviews
pe anti tim3 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
tim3  (R&D Systems)
94
R&D Systems tim3
(A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
Tim3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tim3/product/R&D Systems
Average 94 stars, based on 1 article reviews
tim3 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier
galectin 9 tim3  (Galectin Therapeutics)
86
Galectin Therapeutics galectin 9 tim3
(A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
Galectin 9 Tim3, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/galectin 9 tim3/product/Galectin Therapeutics
Average 86 stars, based on 1 article reviews
galectin 9 tim3 - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
tim3 galectin 9 expression  (Galectin Therapeutics)
86
Galectin Therapeutics tim3 galectin 9 expression
(A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
Tim3 Galectin 9 Expression, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tim3 galectin 9 expression/product/Galectin Therapeutics
Average 86 stars, based on 1 article reviews
tim3 galectin 9 expression - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
protein 3 tim3  (Galectin Therapeutics)
86
Galectin Therapeutics protein 3 tim3
(A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, <t>TIM3+</t> T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.
Protein 3 Tim3, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein 3 tim3/product/Galectin Therapeutics
Average 86 stars, based on 1 article reviews
protein 3 tim3 - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


(A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.

Journal: bioRxiv

Article Title: Single-Cell Profiling Reveals Developmental Trajectories and identifies SYK and TIM3 as Targets in some T Cell Lymphomas

doi: 10.64898/2026.03.27.714741

Figure Lengend Snippet: (A) A UMAP showing the integration of tumour and benign cells of the TME, and healthy lymph node data from two public studies (PMID35027729, PMID39566559). Cells are coloured according to the data source, and scANVI-predicted cell types are shown in (B), (C) and (D). Images of an ALK+ ALCL case colored by Cell2location-predicted cell type abundances in each Visium spot. (C) Predictions for the locations of malignant cells, TIM3+ T cells (T_TIM3+) and cytotoxic T cells (T_CD8+_cytotoxic), (D) Predictions for the locations of dark zone B cells (B_GC_DZ), light zone B cells (B_GC_LZ) and follicular dendritic cells (FDC). (E) A dotplot showing non-negative matrix factorisation (NMF) factors, where each factor is a group of co-localized cell types. In the dotplot, the size and color density represent the loading of each cell type in each factor. (F) Staining of TIM3 and CD30 expression on two representative ALK+ ALCL cases (G) Summary of the % TIM3+ infiltrating T lymphocytes in each of the 9 ALK+ ALCL cases analysed.

Article Snippet: Following heat-mediated antigen retrieval, consecutive sections were stained for TIM3 (MAB23652, R&D Systems) and CD30 (M0751, Agilent Dako) both at a 1:50 dilution.

Techniques: Staining, Expressing